In Brief: Abortion kit
Abortion kit: FDA halts promotion of home abortion and self-sterilization kits marketed through the Internet. The self-sterilization kit uses the unapproved drug quinacrine, and the abortion kit uses an unapproved combination of methotrexate and misoprostol (Searle's Cytotec). In a June 17 "Talk Paper," FDA states that use of the kits without a physician's supervision could lead to heavy vaginal bleeding, abnormal pregnancies and birth defects, permanent damage to reproductive organs and death. Although FDA does not know who is responsible for the products, it has removed promotional materials from the Internet by contacting the Web site's server...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth